Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

Next Previous
Trial Profile

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferasirox (Primary) ; Deferiprone (Primary)
  • Indications Iron overload
  • Focus Therapeutic Use
  • Acronyms START
  • Sponsors ApoPharma; Chiesi

    • Most Recent Events

    • 17 Jun 2022 Primary endpoint (The percentage of patients in each treatment group who still have a serum ferritin level 1000 micrograms per liter (g/L) at Month 12) has been met, as per results presented at the 27th Congress of the European Haematology Association.
    • 17 Jun 2022 Results assessing ability of early-start DFP to shuttle iron to transferrin in infants and young children with transfusion-dependent beta thalassemia using transferrin-saturation (TSAT) measurements, presented at the 27th Congress of the European Haematology Association.
    • 14 Dec 2021 Results assessing safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top